Drug Trial Radar · NCT00542412
CARE Canadian ALS Riluzole Evaluation
Last checked: Nov 20, 2026Latest source record: Oct 11, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
414
Actual
Start
Jan 2001
Primary completion
Not stated
Study completion Dec 2004
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Oct 11, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the efficacy of riluzole 50-mg bid defined by comparing the percentage of riluzole-treated subjects who experienced death, permanently assisted ventilation (PAV) or tracheostomy, to a group of recent historical controls for the treatment of amyotrophic lateral sclerosis (ALS).
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
RiluzoleDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary efficacy endpoint was the time to the occurrence of an ALS-related event (PAV, tracheostomy or ALS-related death)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sanofi-Aventis
Laval, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.